The Bruton's tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody-mediated T-cell cytotoxicity

被引：4
|
作者：
Godwin, Colin D. [1 ,2 ]
Bates, Olivia M. [1 ]
Garling, Eliotte E. [1 ]
Beddoe, Mary E. [1 ]
Laszlo, George S. [1 ]
Walter, Roland B. [1 ,2 ,3 ,4 ]
机构：
[1] Univ Washington, Fred Hutchinson Canc Res Ctr, Clin Res Div, Seattle, WA 98195 USA
[2] Univ Washington, Dept Med, Div Hematol, Seattle, WA 98195 USA
[3] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
[4] Univ Washington, Dept Pathol, Seattle, WA 98195 USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2020年 / 189卷 / 01期
基金：
美国国家卫生研究院;
关键词：
acute leukaemia; bispecific antibody; Bruton's tyrosine kinase; ibrutinib; IL-2-inducible T-cell kinase;
D O I：
10.1111/bjh.16406
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E9 / +
页数：5
相关论文
共 50 条
  • [1] The role of apoptosis in bispecific antibody-mediated T-cell cytotoxicity
    Kroesen, BJ
    Wellenberg, GJ
    Bakker, A
    Helfrich, W
    The, TH
    deLeij, L
    BRITISH JOURNAL OF CANCER, 1996, 73 (06) : 721 - 727
  • [2] Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies
    Gayko, Urte
    Fung, Mann
    Clow, Fong
    Sun, Steven
    Faust, Elizabeth
    Price, Samiyeh
    James, Danelle
    Doyle, Margaret
    Bari, Samina
    Zhuang, Sen Hong
    PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: PRIX GALIEN 2014, 2015, 1358 : 82 - 94
  • [3] Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
    Woyach, Jennifer A.
    Furman, Richard R.
    Liu, Ta-Ming
    Ozer, Hatice Gulcin
    Zapatka, Marc
    Ruppert, Amy S.
    Xue, Ling
    Li, Daniel Hsieh-Hsin
    Steggerda, Susanne M.
    Versele, Matthias
    Dave, Sandeep S.
    Zhang, Jenny
    Yilmaz, Ayse Selen
    Jaglowski, Samantha M.
    Blum, Kristie A.
    Lozanski, Arletta
    Lozanski, Gerard
    James, Danelle F.
    Barrientos, Jacqueline C.
    Lichter, Peter
    Stilgenbauer, Stephan
    Buggy, Joseph J.
    Chang, Betty Y.
    Johnson, Amy J.
    Byrd, John C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (24): : 2286 - 2294
  • [4] The Bruton tyrosine kinase inhibitor ibrutinib abrogates triggering receptor on myeloid cells 1-mediated neutrophil activation
    Stadler, Nicole
    Hasibeder, Astrid
    Lopez, Pamela Aranda
    Teschner, Daniel
    Desuki, Alexander
    Kriege, Oliver
    Weber, Alexander N. R.
    Schulz, Christoph
    Michel, Christian
    Hess, Georg
    Radsak, Markus P.
    HAEMATOLOGICA, 2017, 102 (05) : E191 - E194
  • [5] Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase
    Davids, Matthew S.
    Brown, Jennifer R.
    FUTURE ONCOLOGY, 2014, 10 (06) : 957 - 967
  • [6] The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy
    Castellani, Francesca
    Visentin, Andrea
    Campagnolo, Marta
    Salvalaggio, Alessandro
    Cacciavillani, Mario
    Candiotto, Cinzia
    Bertorelle, Roberta
    Trentin, Livio
    Briani, Chiara
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2020, 7 (04):
  • [7] Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib
    Liu, Linyi
    Shi, Bingyu
    Wang, Xiangqian
    Xiang, Hua
    FUTURE MEDICINAL CHEMISTRY, 2018, 10 (03) : 343 - 356
  • [8] Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis
    Brochard, J.
    Morio, F.
    Mahe, J.
    Le Pape, P.
    Guimard, T.
    Mahe, B.
    Leterrier, M.
    Morrier, M.
    Raffi, F.
    Boutoille, D.
    MEDECINE ET MALADIES INFECTIEUSES, 2020, 50 (08): : 742 - 745
  • [9] Ibrutinib, an oral inhibitor of Bruton's tyrosine kinase, is active in anti-MAG antibody polyneuropathy.
    Briani, C.
    Visentin, A.
    Castellani, F.
    Campagnolo, M.
    Salyalaggio, A.
    Cacciavillanil, M.
    Candiotto, C.
    Bertorelle, R.
    Trentin, L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 401 - 401
  • [10] The Promising Impact of Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor, for the Management of Lymphoid Malignancies
    Bhatt, Valkal
    Alejandro, Linh
    Michael, Angela
    Ganetsky, Alex
    PHARMACOTHERAPY, 2014, 34 (03): : 303 - 314
12345